SPX -0.03% VIX -2.13%
LEAR CUTS SALES AND EARNINGS GUIDANCE 
U.S. IMPORT-PRICES DATA PROVIDE LATEST EVIDENCE OF WEAK INFLATION 
WELLS FARGO SHARES SLIP IN PREMARKET EVEN AS EARNINGS BLOW BY TARGET 
U.S. RETAIL SALES PICK UP MORE THAN FORECAST IN JUNE 
NEED TO KNOW: CORRELATION BETWEEN 10-YEAR NOTE AND S&P 500 CALLED 'EXTREME' 
ASSANGE TURNED EMBASSY IN LONDON INTO COMMAND POST FOR ELECTION ATTACK: CNN 
BLUE APRON SHARES RALLY ON ANNOUNCEMENT OF BEYOND MEAT RECIPES 
JOHNSON & JOHNSON SHARES UP IN PREMARKET AFTER EARNINGS TOP TARGET 
GOLDMAN SACHS SHARES ON RISE AFTER SECOND-QUARTER EARNINGS REPORT 
DOMINO'S PIZZA STOCK FALLS MORE THAN 5% AFTER EARNINGS REPORT 
Tue, Jul 16 10:17am

Compare ICPT



Intercept Pharmaceuticals Inc [ICPT]
$69.92 0.64 (0.92%)

ICPT Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 2.27 Billion
ICPT Description

Intercept Pharmaceuticals is a biotech company focused on developing and commercializing novel therapeutics to treat chronic liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH. Intercept owns worldwide rights to OCA outside of China, where it has licensed out the product to Sumitomo Dainippon Pharma.


Visit Website

ICPT Earnings

EPS -3.03 P/E Ratio 0.00
Previous Earnings Thu, Feb 28, 2019
Latest Earnings Wed, May 8, 2019 (69 days ago) -18.01%

ICPT Dividend

Yield --
Ex-Date --
Pay Date --
History --

ICPT Charts

$68.20
52 Week Range
$127.89
Jul 15, 2019
Sep 27, 2018



Symbol Price Day % YTD %
ICPT $69.92 0.92% -28.10%

Symbol Surfing

How can we make Symbol Surfing better?

info@symbolsurfing.com

Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.



©2019 Symbol Surfing All Rights Reserved.

Cookies Policy | Terms Of Service | Privacy Policy